PDF(Pubmed)
Abstract：
UNASSIGNED: Hyperprolactinemia is a common antipsychotic-induced adverse event in psychiatric patients, and the quality of clinical studies investigating the best treatments has varied. Thus, to better summarize the clinical evidence, we performed an umbrella review of overlapping systematic reviews and meta-analyses for the treatment of antipsychotic-induced hyperprolactinemia.
UNASSIGNED: The PubMed, Cochrane Library, PsycINFO, Scopus and EMBASE were searched, and reviews and meta-analyses meeting our inclusion criteria were selected. Relevant data were extracted, and an umbrella review was conducted of all included meta-analyses. The quality of included meta-analyses was assessed by using PRISMA scores and AMSTAR 2 quality evaluation. Finally, the clinical evidence for appropriate treatments was summarized and discussed.
UNASSIGNED: Five meta-analyses published between 2013 and 2020 met the requirements for inclusion in this umbrella review. The PRISMA scores of the included meta-analyses ranged from 19.5-26. AMSTAR 2 quality evaluation showed that 2 of the 5 included meta-analyses were of low quality and 3 were of very low quality. The included meta-analyses provide clinical evidence that adding aripiprazole or a dopamine agonist can effectively and safely improve antipsychotic-induced hyperprolactinemia. Two meta-analyses also showed that adjunctive metformin can reduce serum prolactin level, but more clinical trials are needed to confirm this finding.
UNASSIGNED: Adjunctive dopamine agonists have been proven to be effective and safe for the treatment of antipsychotic-induced hyperprolactinemia. Among the researched treatments, adding aripiprazole may be the most appropriate.
UNASSIGNED: The PubMed, Cochrane Library, PsycINFO, Scopus and EMBASE were searched, and reviews and meta-analyses meeting our inclusion criteria were selected. Relevant data were extracted, and an umbrella review was conducted of all included meta-analyses. The quality of included meta-analyses was assessed by using PRISMA scores and AMSTAR 2 quality evaluation. Finally, the clinical evidence for appropriate treatments was summarized and discussed.
UNASSIGNED: Five meta-analyses published between 2013 and 2020 met the requirements for inclusion in this umbrella review. The PRISMA scores of the included meta-analyses ranged from 19.5-26. AMSTAR 2 quality evaluation showed that 2 of the 5 included meta-analyses were of low quality and 3 were of very low quality. The included meta-analyses provide clinical evidence that adding aripiprazole or a dopamine agonist can effectively and safely improve antipsychotic-induced hyperprolactinemia. Two meta-analyses also showed that adjunctive metformin can reduce serum prolactin level, but more clinical trials are needed to confirm this finding.
UNASSIGNED: Adjunctive dopamine agonists have been proven to be effective and safe for the treatment of antipsychotic-induced hyperprolactinemia. Among the researched treatments, adding aripiprazole may be the most appropriate.
摘要：
■高催乳素血症是精神病患者常见的抗精神病药物引起的不良事件，研究最佳治疗方法的临床研究质量各不相同。因此，为了更好地总结临床证据，我们对抗精神病药物诱导的高催乳素血症治疗的相互重叠的系统评价和荟萃分析进行了综述.
■PubMed，科克伦图书馆,PsycINFO,搜索了Scopus和EMBASE,我们选择了符合我们纳入标准的综述和荟萃分析.提取相关数据,并对所有纳入的荟萃分析进行了综述.通过使用PRISMA评分和AMSTAR2质量评估来评估纳入的荟萃分析的质量。最后,总结并讨论了适当治疗的临床证据。
■在2013年至2020年之间发布的五项荟萃分析符合纳入本总括审查的要求。纳入的荟萃分析的PRISMA评分范围为19.5-26。AMSTAR2质量评估显示，5项纳入的荟萃分析中有2项质量低，3项质量非常低。纳入的荟萃分析提供了临床证据，表明添加阿立哌唑或多巴胺激动剂可以有效且安全地改善抗精神病药物引起的高催乳素血症。两项荟萃分析还显示，辅助二甲双胍可以降低血清催乳素水平，但需要更多的临床试验来证实这一发现。
■辅助多巴胺激动剂已被证明对治疗抗精神病药引起的高催乳素血症有效且安全。在研究的治疗方法中，加用阿立哌唑可能是最合适的。
■PubMed，科克伦图书馆,PsycINFO,搜索了Scopus和EMBASE,我们选择了符合我们纳入标准的综述和荟萃分析.提取相关数据,并对所有纳入的荟萃分析进行了综述.通过使用PRISMA评分和AMSTAR2质量评估来评估纳入的荟萃分析的质量。最后,总结并讨论了适当治疗的临床证据。
■在2013年至2020年之间发布的五项荟萃分析符合纳入本总括审查的要求。纳入的荟萃分析的PRISMA评分范围为19.5-26。AMSTAR2质量评估显示，5项纳入的荟萃分析中有2项质量低，3项质量非常低。纳入的荟萃分析提供了临床证据，表明添加阿立哌唑或多巴胺激动剂可以有效且安全地改善抗精神病药物引起的高催乳素血症。两项荟萃分析还显示，辅助二甲双胍可以降低血清催乳素水平，但需要更多的临床试验来证实这一发现。
■辅助多巴胺激动剂已被证明对治疗抗精神病药引起的高催乳素血症有效且安全。在研究的治疗方法中，加用阿立哌唑可能是最合适的。
